Autoimmune Uveitis Market to Expand at a CAGR of 7% During the Forecast Period (2026-2036) as Novel Treatments Challenge the Existing Therapeutic Landscape | DelveInsight

The autoimmune uveitis market is estimated at $1.2B in the 7MM in 2025 (with ~673,000 diagnosed prevalent cases), projected to grow at a 7% CAGR through 2036, supported by rising non-infectious uveitis diagnoses and demand for steroid-sparing options. The article highlights a growing pipeline—e.g., Priovant’s brepocitinib (TYK2/JAK1) in late-stage NIU studies with topline expected in 2H26, plus Tarsier’s TRS01 and Chugai’s RAY121—aimed at improving efficacy, durability, and safety. Recent regulatory and clinical progress (e.g., FDA IND clearance for Novaliq’s NOV05 Phase II EYETAC, and Fast Track for brepocitinib) suggests incremental positive momentum for future market expansion.

Analysis

This reads more like category validation than a tradable catalyst. The real market mechanism is not near-term revenue, but the probability that ophthalmology-specific delivery wins share from chronic steroid and broad immunosuppressant use; that shift benefits companies with localized delivery or differentiated tolerability far more than it benefits large-cap systemic immunology franchises. For ABBV, any uveitis upside is too small to move the P&L, but the signal is that adalimumab’s incumbent position may face gradual mix pressure if safer, local therapies prove out.

The winners on a 12-24 month view are the option-value names with clean clinical readouts, especially CHGCY and smaller pipeline players, because a single positive efficacy/safety dataset could re-rate them before any commercial launch. The loser is the market’s tendency to price the TAM as if diagnosis growth automatically converts to premium biologic revenue; reimbursement and physician switching are the bottlenecks, not prevalence. If topical or localized agents work, they may expand treated patients but compress ASPs versus systemic biologics.

The contrarian view is that the consensus is probably overestimating how quickly this becomes a meaningful investable subsegment. Most of the pipeline remains binary and multi-year away, and the most likely near-term outcome is continued fragmentation across cheap steroids, off-label immunosuppressants, and one incumbent biologic. A clinical miss from brepocitinib or any safety issue in ocular delivery would likely deflate the whole theme faster than the market currently implies, so the best trade is patience, not anticipation.

Key Decisions for Investors

• Do not chase the theme today: no high-conviction outright trade in ABBV from this report alone; the uveitis franchise is too small to alter 1-3 month fundamentals, and any positive read-through is already partially embedded in immunology expectations.
• Keep CHGCY on a watchlist into H2-2026 data flow: if RAY121 shows clean tolerability plus durable control, a long-biased position can work as an option on ophthalmology-specific differentiation, but only after clinical de-risking.
• Avoid pre-launch smaller-cap names as a basket long on this report; the better asymmetry is to wait for confirmation and then buy weakness after the first data pop, since market-access and trial-design risk remain the main falsifiers.
• If seeking a relative-value expression, prefer long ABBV versus a basket of pre-commercial ocular developers only after any speculative run-up; the thesis is that incumbency monetizes while the pipeline is still years from revenue, with a superior drawdown profile.
• Set a catalyst alert for brepocitinib H2-2026 topline: a clear efficacy miss or safety signal would be a fast de-risking event for the entire autoimmune-uveitis tape; above that, the trade becomes a dispersion story rather than a sector-wide re-rating.